Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Papp

Showing results (101-110 of 137) with videos related to

Pageof 14
Sort By:
Pediatrics|July 3, 2002
Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in childrenUlrich Wahn, Jan D Bos, Mark Goodfield, et al.
The Journal of Allergy and Clinical Immunology|August 10, 2002
Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drugAlexander Kapp, Kim Papp, Ann Bingham, et al.
Rheumatology and Therapy|March 18, 2024
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical TrialLars Erik Kristensen, Mauro Keiserman, Kim Papp, et al.
The Journal of Investigative Dermatology|April 4, 2016
A Highly Sensitive and Drug-Tolerant Anti-Drug Antibody Screening Assay for Ixekizumab using Affinity Capture ElutionTalia M Muram, John H Sloan, Jana S Chain, et al.
Journal of the American Academy of Dermatology|September 16, 2022
Itch-free state in patients with atopic dermatitis treated with ruxolitinib cream: A pooled analysis from two randomized phase 3 studiesAndrew Blauvelt, Jacek C Szepietowski, Kim Papp, et al.
Annals of the Rheumatic Diseases|November 24, 2021
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trialAndrew Östör, Filip Van den Bosch, Kim Papp, et al.
Journal of the American Academy of Dermatology|October 11, 2017
Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trialBoni E Elewski, Martin M Okun, Kim Papp, et al.
Journal of the American Academy of Dermatology|May 6, 2021
Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studiesKim Papp, Jacek C Szepietowski, Leon Kircik, et al.
Rheumatology and Therapy|March 18, 2024
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical TrialAndrew Östör, Filip Van den Bosch, Kim Papp, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 15, 2023
Guselkumab for the treatment of patients with moderate-to-severe hidradenitis suppurativa: A phase 2 randomized studyAlexa B Kimball, Maurizio Podda, Afsaneh Alavi, et al.
Pageof 14

Showing results (101-110 of 137) with videos related to

Sort By:
Pageof 14
Pediatrics|July 3, 2002
Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in childrenUlrich Wahn, Jan D Bos, Mark Goodfield, et al.
The Journal of Allergy and Clinical Immunology|August 10, 2002
Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drugAlexander Kapp, Kim Papp, Ann Bingham, et al.
Rheumatology and Therapy|March 18, 2024
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical TrialLars Erik Kristensen, Mauro Keiserman, Kim Papp, et al.
The Journal of Investigative Dermatology|April 4, 2016
A Highly Sensitive and Drug-Tolerant Anti-Drug Antibody Screening Assay for Ixekizumab using Affinity Capture ElutionTalia M Muram, John H Sloan, Jana S Chain, et al.
Journal of the American Academy of Dermatology|September 16, 2022
Itch-free state in patients with atopic dermatitis treated with ruxolitinib cream: A pooled analysis from two randomized phase 3 studiesAndrew Blauvelt, Jacek C Szepietowski, Kim Papp, et al.
Annals of the Rheumatic Diseases|November 24, 2021
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trialAndrew Östör, Filip Van den Bosch, Kim Papp, et al.
Journal of the American Academy of Dermatology|October 11, 2017
Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trialBoni E Elewski, Martin M Okun, Kim Papp, et al.
Journal of the American Academy of Dermatology|May 6, 2021
Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studiesKim Papp, Jacek C Szepietowski, Leon Kircik, et al.
Rheumatology and Therapy|March 18, 2024
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical TrialAndrew Östör, Filip Van den Bosch, Kim Papp, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 15, 2023
Guselkumab for the treatment of patients with moderate-to-severe hidradenitis suppurativa: A phase 2 randomized studyAlexa B Kimball, Maurizio Podda, Afsaneh Alavi, et al.
Pageof 14